secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001104659-26-028103
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics raises $17M via Atlas note to partially repay Avondale debt; going concern warning
--------------------------------------------------------------------------------

- Issued $18.36M unsecured note (net $17M after OID) to Atlas Sciences; proceeds used to repay $17M of $33.1M Avondale Note.
- Remaining Avondale Note balance of ~$10.8M; maturity extended to Dec 31, 2026 via amendment.
- Atlas note: interest prime+3% (floor 9.5%), matures 15 months from March 16, 2026; quarterly redemption up to $3M; 7.5% exit fee.
- Supplemental risk factors state substantial doubt about going concern; cash insufficient for next 12 months.
- FDA issued third Complete Response Letter for ONS-5010 in Dec 2025; Type A meeting held March 2026 with no clear path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/0001104659-26-028103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-028103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer